{"id":"i-131-1095","_chembl":{"chemblId":"CHEMBL4297853","moleculeType":"Unknown"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"PSMA (Prostate-Specific Membrane Antigen)","explanation":"I-131-1095 is a radiolabeled small molecule that selectively binds to PSMA, a cell surface protein highly expressed in prostate cancer cells. Upon binding, the iodine-131 radioisotope delivers beta radiation directly to tumor cells, enabling both imaging and targeted radiotherapy of PSMA-positive lesions.","oneSentence":"I-131-1095 binds to prostate-specific membrane antigen (PSMA) and delivers targeted radiation to PSMA-expressing cancer cells."},"_scrapedAt":"2026-03-28T03:34:29.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123923,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"lutetium Lu 177 vipivotide tetraxetan","brand":"Pluvicto","company":"Novartis","rationale":"PSMA-targeted radioligand therapy for metastatic prostate cancer"},{"name":"lutetium Lu 177 dotatate","brand":"Lutathera","company":"Novartis","rationale":"Radiolabeled therapeutic for cancer treatment"}],"description":"I-131-1095 is an investigational radioiodinated small molecule imaging and therapeutic agent developed by Progenics Pharmaceuticals. The compound is designed to target prostate-specific membrane antigen (PSMA) for detection and treatment of prostate cancer, currently in Phase 2 clinical development.","indications":{"approved":[{"status":"investigational","condition":"Prostate cancer","patientPopulation":"Adult patients with metastatic castration-resistant prostate cancer"}]},"trialDetails":[{"nctId":"NCT03939689","phase":"PHASE2","title":"I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).","status":"COMPLETED","sponsor":"Progenics Pharmaceuticals, Inc.","startDate":"2019-05-30","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["131 I-PSMA-1095","131I-LNTH-1095"],"phase":"phase_2","status":"active","brandName":"I-131-1095","genericName":"I-131-1095","companyName":"Progenics Pharmaceuticals, Inc.","companyId":"progenics-pharmaceuticals-inc","firstApprovalDate":"","aiSummary":"I-131-1095 is a radioligand being studied in a Phase 2 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has progressed during abiraterone treatment. In this trial, I-131-1095 is being compared to the medication Enzalutamide for efficacy and safety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}